Physician profile
Mark Cwern
NPI 1780661769
$796.67
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $667.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $315.68 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.82 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.20 | 2022 | |
| Daiichi Sankyo INC. | $66.24 | 2022 | |
| Merck Sharp & Dohme LLC | $49.76 | 2021-2022 | |
| Pfizer INC. | $47.00 | 2022 | |
| Celgene Corporation | $31.86 | 2022 | |
| Janssen Biotech, INC. | $31.60 | 2022 | |
| Phadia US INC. | $17.57 | 2022 | |
| Currax Pharmaceuticals LLC | $12.94 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cwern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.